Drug Profile
BR 2002
Alternative Names: BR-2002Latest Information Update: 21 Aug 2023
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer
Most Recent Events
- 21 Aug 2023 Phase-II clinical trials in Cancer in unknown location (Boryung Pharmaceutical pipeline, August 2023)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Cancer in South Korea
- 20 May 2020 Phase-I clinical trials in Cancer in South Korea (unspecified route), prior to May 2020 (Boryung Pharmaceutical pipeline, May 2020)